PF-05175157

Generic Name
PF-05175157
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H27N5O2
CAS Number
1301214-47-0
Unique Ingredient Identifier
P826WR56FI
Background

PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others.

Associated Conditions
-
Associated Therapies
-

Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2014-04-01
Last Posted Date
2014-05-13
Lead Sponsor
Pfizer
Registration Number
NCT02100527

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2014-02-03
Last Posted Date
2016-05-02
Lead Sponsor
Pfizer
Target Recruit Count
13
Registration Number
NCT02053103
Locations
🇺🇸

Pfizer Investigational Site, Orlando, Florida, United States

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2014-02-03
Last Posted Date
2016-05-02
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT02053116
Locations
🇺🇸

Pfizer Investigational Site, DeLand, Florida, United States

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-03-29
Last Posted Date
2013-05-21
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01821079
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-03-28
Last Posted Date
2016-05-02
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01819922
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

First Posted Date
2013-03-08
Last Posted Date
2013-09-17
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT01807377
Locations
🇺🇸

Pfizer Investigational Site, Chula Vista, California, United States

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-02-15
Last Posted Date
2017-02-16
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT01792635
Locations
🇺🇸

Profil Institute for Clinical Research, Inc., Chula Vista, California, United States

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

First Posted Date
2012-12-31
Last Posted Date
2012-12-31
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01757756
Locations
🇺🇸

Pfizer Investigational Site, South Miami, Florida, United States

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-02-23
Last Posted Date
2012-07-10
Lead Sponsor
Pfizer
Target Recruit Count
31
Registration Number
NCT01537497
Locations
🇺🇸

Pfizer Investigational Site, South Miami, Florida, United States

A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-11-10
Last Posted Date
2018-11-14
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT01469468
Locations
🇺🇸

Pfizer Investigational Site, South Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath